Carisma Therapeutics, Inc. (SESN) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

CorMedix, Inc.

Verastem, Inc.

Foghorn Therapeutics, Inc.

Carisma Therapeutics, Inc.

Fate Therapeutics, Inc.

Lineage Cell Therapeutics, Inc.

Invivyd, Inc.

Taysha Gene Therapies, Inc.

Synlogic, Inc.

Neoleukin Therapeutics, Inc.

Vigil Neuroscience, Inc.

Why is Carisma Therapeutics, Inc. ?

Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -46.94

With a growth in Net Sales of 1236.78%, the company declared Outstanding results in Sep 25

OPERATING CASH FLOW(Y) Highest at USD -22.41 MM
NET SALES(HY) Higher at USD 45.25 MM
DEBTORS TURNOVER RATIO(HY) Highest at 64.34 times

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -85.23%, its profits have risen by 114.1%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -85.23% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Carisma Therapeutics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Carisma Therapeutics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Carisma Therapeutics, Inc.

-85.23%

-0.52

188.77%

S&P 500

15.36%

1.17

13.09%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

36.17%

EBIT Growth (5y)

18.53%

EBIT to Interest (avg)

-46.94

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.17

Sales to Capital Employed (avg)

-4.66

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

18.67%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

-1.38

EV to EBIT

-0.11

EV to EBITDA

-0.09

EV to Capital Employed

0.36

EV to Sales

-0.02

PEG Ratio

Dividend Yield

ROCE (Latest)

-310.71%

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bullish

Bearish

Bollinger Bands

Mildly Bearish

Sideways

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is working for Carisma Therapeutics, Inc.

Net Sales

At USD 45.25 MM has Grown at 259.64%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (USD MM)

Pre-Tax Profit

At USD 44.72 MM has Grown at 452.05%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit

At USD 44.72 MM has Grown at 452.05%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Operating Cash Flow

Highest at USD -22.41 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Sales

Higher at USD 45.25 MM

than preceding 12 month period ended Sep 2025

MOJO Watch

In the half year the company has already crossed sales of the previous twelve months

Net Sales (USD MM)

Operating Profit

Highest at USD 43.81 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit

Highest at USD 44.72 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD 44.72 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

EPS

Highest at USD 1.07

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Debtors Turnover Ratio

Highest at 64.34 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Carisma Therapeutics, Inc.

Cash and Eqv

Lowest at USD 4.78 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at 232.41 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost

Grown by 101.29% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales